J.P. Morgan Upgrades Hengrui H-shares to Overweight, Valuation Reset Creates Buying Opportunity

Overview

J.P. Morgan published a report upgrading Hengrui Medicine's H-share rating from 'Neutral' to 'Overweight', while maintaining the A-share 'Overweight' rating. The report believes that Hengrui H-shares' recent ~40% correction from 52-week highs, exceeding the decline in the CSI 300 Healthcare Index during the same period, is primarily due to overall sentiment deterioration in China's healthcare sector, US-China geopolitical tensions, and institutional position reductions, rather than substantive adverse changes in the company's fundamentals. At current levels, Hengrui H-shares'/A-shares' forward P/E is approximately 33x/34x, more than two standard deviations below historical averages, failing to fully reflect the company's earnings improvement trend, rapidly expanding pipeline value, and long-term out-licensing (BD) revenue potential. Although the report slightly lowers long-term BD revenue forecasts and target prices (both H-shares and A-shares adjusted to HKD/RMB 68) due to concerns about potential US restrictions on Chinese drug licensing transactions, it emphasizes that the current valuation reset creates a highly attractive re-entry opportunity for long-term investors.

Core views

Core pipeline clinical data continues to validate competitiveness. At the ASCO 2026 conference, two key ADC assets demonstrated strong clinical value. Nectin-4 ADC SHR-A2102 combined with PD-L1 monoclonal antibody for muscle-invasive bladder cancer (MIBC) achieved 48% pathological complete response rate (pCR) and 59.3% pathological downstaging rate in difficult-to-treat populations including those with renal impairment, showing significant tolerability advantages over Pfizer's comparable product and establishing differentiated positioning. HER2 ADC SHR-A1811 became the first ADC to achieve positive Phase III results in refractory HER2-positive colorectal cancer, with objective response rate (ORR) of 32.6% (control group only 4.5%) and significantly prolonged progression-free survival (PFS) (5.6 months vs 2.8 months, HR=0.31). These data indicate that both core assets are steadily advancing toward commercial success in large indication markets. Undervalued cardiology pipeline and globalization BD value. The report specifically highlights HRS-1893 as a long-term value driver overlooked by the market. The drug demonstrated rapid and substantial reduction in left ventricular outflow tract pressure gradient in Phase II trials for obstructive and non-obstructive hypertrophic cardiomyopathy (HCM), with minimal impact on left ventricular ejection fraction (LVEF) and superior safety compared to competitors, possessing the potential to become a category-defining asset. Given the scarcity of approved therapies for non-obstructive HCM and partner Braveheart's exclusive overseas rights, this asset provides a commercialization option not reflected in consensus expectations. Additionally, the strategic collaboration with Bristol Myers Squibb (BMS) covering 13 early-stage projects (potential total deal value of USD 15.2 billion) not only brings certain cash flow but also validates Hengrui's R&D platform's global competitiveness through a 'co-development' model, diversifying its revenue sources and reducing dependence on China's single domestic medical insurance pricing system. Valuation model adjustments and rating logic. Based on potential restrictions on future innovative drug out-licensing due to US-China geopolitical tensions, the report slightly adjusts long-term BD revenue forecasts and lowers H-share/A-share target prices from HKD/RMB 70 to HKD/RMB 68. DCF valuation assumes WACC of 9.6% and terminal growth rate of 3%. Despite the modest target price reduction, considering the valuation attractiveness after H-shares' recent significant correction (forward P/E at historical lows), as well as the company's robust R&D portfolio, sales capabilities, and potential Beta opportunities from fiscal stimulus, the report views the current environment as a buying opportunity and therefore upgrades the H-share rating contrarily.

Analysis framework

The report adopts a 'fundamental and sentiment decoupling' analytical framework. First, by comparing the stock's decline (-40%) with the industry index decline (-32%), it identifies that the excess decline primarily stems from non-operational factors such as macro-geopolitical risks and institutional position adjustments, thereby determining a 'killing by mistake' opportunity when fundamentals remain intact. Second, when evaluating innovative pharmaceutical companies' value, it does not limit itself to current financial statements but adopts a hybrid perspective of 'pipeline peak sales + BD option value': on one hand, it dynamically adjusts core ADC products' commercialization success rates and peak expectations based on latest clinical data from top-tier conferences such as ASCO (e.g., pCR, ORR, PFS); on the other hand, it treats collaborations with multinational pharmaceutical companies such as BMS as third-party endorsements of R&D platform quality, incorporating their upfront and milestone payments into long-term cash flow forecasts. Finally, it uses the DCF model for absolute valuation and explicitly incorporates geopolitical premiums in risk factors, quantifying the impact of external uncertainty on intrinsic value by adjusting BD revenue assumptions.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  Discounted Cash Flow Model (DCF)

  The report uses the DCF model as its core pricing tool, setting WACC at 9.6%, terminal growth rate at 3%, and separately adding early-stage pipeline value (approximately RMB 92.5 billion). This method is suitable for innovative pharmaceutical companies like Hengrui that possess substantial unlisted pipelines where current profits cannot fully reflect future value, as it can quantify the potential monetization capability of R&D pipelines into stock prices.

• Event Game Theory and Behavioral FinanceExpectation Gap/Expectation Management

  Sentiment and Fundamental Divergence Analysis

  The report analyzes the divergence between stock price correction magnitude and industry index decline to distinguish between 'sentiment-driven sell-off' and 'fundamental deterioration.' When stock price declines are primarily driven by macro or geopolitical sentiment while company operating data and pipeline progress remain positive, this divergence often implies investment opportunities arising from expectation gaps.

• Industry/Industrial Analysis Framework

  Pipeline Clinical Data-Driven Value Reassessment

  For innovative pharmaceutical companies, key clinical metrics disclosed at academic conferences such as ASCO (e.g., pCR, ORR, PFS, and safety data) are core milestones for validating products' commercial potential. The report directly adjusts peak sales and success probability estimates by interpreting these data's advantages or disadvantages relative to standard of care (SoC) or competitors—this is the pharmaceutical industry-specific 'data as catalyst' analytical paradigm.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Hengrui Medicine-H (1276.HK)

  Rating upgrade beneficiary: enhanced cost-performance ratio after valuation correction, solid fundamentals

  Strengths

  ADC pipeline data globally leading; BMS collaboration validates platform value; cardiology pipeline possesses BIC potential; valuation at historical lows

  Weaknesses

  Relatively weaker H-share market liquidity; significantly affected by foreign sentiment toward China's healthcare sector

  Comparison

  Significant discount compared to A-shares, greater elasticity in this correction

  Risks

  Continued deterioration of H-share market sentiment; FDA approval risks; ADC clinical data below expectations

• Hengrui Medicine-A (600276.SS)

  Maintain Overweight: domestic innovative drug leader, benefiting from potential fiscal stimulus and industry recovery

  Strengths

  Strong domestic sales network; thickest R&D pipeline domestically; abundant cash flow

  Weaknesses

  Ongoing domestic medical insurance negotiation pressure; BD out-licensing faces geopolitical uncertainty

  Comparison

  Premium valuation compared to H-shares but better liquidity, preferred choice for domestic capital allocation to healthcare

  Risks

  PD-1 FDA application rejected; ADC data below expectations; domestic sales growth slowdown

Key data

• H-share Correction MagnitudeApproximately 40%From 52-week high of HKD 95 to around HKD 53, while CSI 300 Healthcare Index fell 32% during the same period
• Forward PEH-shares approximately 33x / A-shares approximately 34xMore than two standard deviations below historical average
• SHR-A2102 pCR Rate48%Combined with PD-L1 for muscle-invasive bladder cancer, pathological downstaging rate 59.3%
• SHR-A1811 ORR32.6%Phase III data in refractory HER2+ colorectal cancer, control group only 4.5%; PFS HR=0.31
• BMS Collaboration Potential TotalUSD 15.2 billionIncluding upfront and anniversary payments of USD 950 million, covering 13 early-stage projects
• 2026E Adjusted EPSRMB 1.31Down 3.6% from previous forecast of RMB 1.36
• DCF WACC Assumption9.6%Risk-free rate 3.8%, equity risk premium 6.2%-6.6%, Beta 1.0

Impact & implications

The report believes that Hengrui Medicine's current valuation has excessively reflected geopolitical risks while overlooking its substantive progress as a leading Chinese pharmaceutical company in R&D transformation and globalization. For investors, this means that during periods of industry sentiment weakness, the 'killing by mistake' of quality leaders provides opportunities to allocate to long-term growth assets at reasonable prices. BMS's substantial collaboration and excellent ADC pipeline data mark Hengrui's transformation from a pure domestic generic-innovative enterprise to an innovation platform with global competitiveness, with more diversified and counter-cyclical long-term revenue structure. Although near-term BD revenue expectations have been slightly lowered due to geopolitics, this has already been digested by current low valuations. If the policy environment eases or clinical data continues to exceed expectations, significant valuation recovery upside exists.

Risks

• PD-1 inhibitor FDA marketing application in the US may be rejected
• ADC pipeline subsequent clinical data may fall below expectations
• H-share market sentiment may further deteriorate
• US-China geopolitical tensions may restrict future out-licensing transactions

What to watch

• FDA approval progress for Hengrui's PD-1 marketing application
• Subsequent registrational clinical data readouts for ADC pipeline (SHR-A1811, SHR-A2102)
• Further clinical validation of HRS-1893 in non-obstructive cardiomyopathy
• Progress and milestone achievements under early-stage projects in BMS collaboration
• Changes in US policies related to Chinese biotechnology